Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 09, 2023

Role of Molecular Subtyping–Based Platform in Precision Medicine for Heavily Pretreated Metastatic TNBC

Cell Research


Additional Info

Cell Research
Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial
Cell Res 2023 May 01;33(5)389-402, Y Liu, XZ Zhu, Y Xiao, SY Wu, WJ Zuo, Q Yu, AY Cao, JJ Li, KD Yu, GY Liu, J Wu, T Sun, JW Cui, Z Lv, HP Li, XY Zhu, YZ Jiang, ZH Wang, ZM Shao

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading